BioPharma Resources

Drug Trial Radar · NCT07056309

A Study of Remternetug (LY3372993) in Healthy Participants

A Study on Pharmacokinetics of Remternetug Administered Subcutaneously Through an Autoinjector Versus Prefilled Syringe in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Jun 24, 2025

Primary completion

Dec 15, 2025

Study completion Dec 15, 2025

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jul 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations. Participation in the study will last approximately 155 days.

Conditions

  • Healthy

Interventions

  • Remternetug (Test)Drug

    Administered SC

  • Remternetug (Reference)Drug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK): Maximum Concentration (Cmax) of RemternetugTime frame: Predose up to Day 85
  2. Pharmacokinetic (PK): Area Under the Concentration Versus Time Curve from Zero to time t [AUC(0-t)] of RemternetugTime frame: Predose up to Day 85
  3. Pharmacokinetic (PK): Area Under the Concentration Versus Time Curve from Zero to Infinity [AUC(0-inf)] of RemternetugTime frame: Predose up to Day 85

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida

  • QPS Missouri

    Springfield, Missouri

  • Fortrea Clinical Research Unit

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.